臨床化学分析装置の世界市場 - 2023年～2030年
Global Clinical Chemistry Analyzers Market -2023-2030
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
|臨床化学分析装置の世界市場 - 2023年～2030年|
発行: DataM Intelligence
ページ情報: 英文 187 Pages
さらに、2021年2月3日、MedTest Holdings, Inc.は、HORIBA Instrumentsのアーバイン本社と株式会社堀場製作所の京都本社に買収されました。この買収により、堀場メディカルは、ポインテサイエンティフィック社とメドテスト社の優れた化学製品の革新的な技術を活用しながら、体外診断用医薬品市場の多分野にわたるニーズに応えることができるようになります。
The global clinical chemistry analyzers market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Clinical chemistry analyzers are crucial parts of automated medical laboratory equipment. These devices examine and characterize the fluid sample composition of biological samples like blood or urine. Advanced chemical or optical methods can be used to do this; however, more on that in a moment.
Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced fully automatic clinical chemistry analyzers or semi-automatic clinical chemistry analyzers and boost the global clinical chemistry analyzers market. The respective innovative chemistry analyzers are in two modalities including bench-top and floor standing.
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for clinical chemistry analyzers owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On February 2, 2023, a multi-year arrangement with a value of more than €200 million was started by Siemens Healthineers, a renowned provider of medical equipment, and Unilabs, a renowned supplier of diagnostic services. Unilabs has invested in cutting-edge technology from Siemens Healthineers and will buy more than 400 scientific analyzers to further upgrade its laboratory infrastructure and provide its clients with unmatched service.
Additionally, on February 3, 2021, MedTest Holdings, Inc. has been purchased by the Irvine headquarters of HORIBA Instruments and the Kyoto, Japan headquarters of HORIBA, Ltd. Through this acquisition, HORIBA Medical will have the chance to serve the multidisciplinary needs of the IVD market while utilizing Pointe Scientific's and MedTest's superior Chemistry products' complimentary revolutionary technologies.
Furthermore, the rising utilization of novel technology and different types of clinical chemistry analyzers for the several research purposes. Rising chronic disorders and increasing research for innovative diagnostic product development will be a major factor driving the growth of the clinical chemistry analyzers market.
Although the cost of kits or consumables, as well as the cost of the CPRT, are some of the criteria that may affect the type of instrument to be purchased or utilized in a clinical chemistry laboratory, the cost of the equipment in modern clinical chemistry laboratories is expensive.
Biochemistry analyzers involve a large initial investment; top-of-the-line models can cost up to $45,000. Because of their high acquisition prices, users like hospitals are forced to purchase them through rental agreements, which lowers sales.
The global clinical chemistry analyzers market is segmented based on product type, modality, application, end user and region.
Fully automated chemical analyzers make it easier and more efficient to complete analytical tasks in various laboratory environments. Researchers can get evaluation results from these tools with exceptional precision. Get analysis reports in the shortest amount of time possible. A variety of diagnostic tasks are performed using fully automated chemical analyzers, including routine examination of albumin, glucose, creatinine, bilirubin, or inorganic phosphorus.
These are also employed in the execution of assays for the evaluation of lipids, therapeutic medications, illicit drugs, and more. Fully automated chemistry analyzers make it possible to do a variety of research tasks more quickly and deliver data in the shortest amount of time.
On June 8, 2023, the most recent offering from Mindray is the M1000 Chemistry with Immunoassay Integrated Solution, which combines an intelligent sample delivery module with two cutting-edge analyzers: the Chemiluminescence Immunoassay Analyzer CL-8000i and the state-of-the-art Chemistry Analyzer BS-2800M. Since its introduction, the solution has received a great deal of customer support and appreciation for its high degree of accuracy, effectiveness, and resilience, especially for the creative design and potent features of the experimental treatment system.
Due to the rising need for clinical chemistry analyzers in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for clinical chemistry analyzers.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of clinical chemistry analyzers market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as fully automatic clinical chemistry analyzers. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global clinical chemistry analyzers market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for clinical chemistry analyzers in the U.S. United States have been proactive in executing several initiatives or researches, stimulating clinical chemistry analyzers demand.
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global clinical chemistry analyzers market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for clinical chemistry analyzers. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global clinical chemistry analyzers market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like bench-top analyzers.
The major global players in the market include: F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., HORIBA Medical, Siemens Healthcare Private Limited, Hitachi High-Tech Corporation, Thermo Fisher Scientific Inc., EKF Diagnostics Holdings plc, Abbott, Mindray Medical India Pvt. Ltd. And Randox Laboratories Ltd. Among others.
The global clinical chemistry analyzers market report would provide approximately 69 tables, 66 figures and 186 Pages.
LIST NOT EXHAUSTIVE